A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer
Journal article published in 2019 by
Ryan J. Brisson 
,
Sara Kochanny,
Saba Arshad,
Allison Dekker,
Jonas A. DeSouza,
Vassiliki Saloura,
Everett E. Vokes,
Tanguy Y. Seiwert
,
Sara Kochanny,
Saba Arshad,
Allison Dekker,
Jonas A. DeSouza,
Vassiliki Saloura,
Everett E. Vokes,
Tanguy Y. Seiwert
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 